

Plasma Neurofilament Light Chain predicts cognitive progression in prodromal and clinical dementia with Lewy Bodies

Andrea Pilotto, MD^{a,b,*\$} and Alberto Imarisio, MD^{a\$}, Claudia Carrarini, MD^c, Mirella Russo, MD^c, Stefano Masciocchi, MD^a, Stefano Gipponi, MD^a, Elisabetta Cottini, MD^a, Dag Aarsland^e, Henrik Zetterberg, MD, PhD^{f,g,h,i}, Nicholas J. Ashton, MSc, PhD^{f,j,k,l}, Abdul Hye, PhD^{k,l}, Laura Bonanni, MD, PhD^c and Alessandro Padovani, MD, PhD^a

^a Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

^b FERB Onlus, Ospedale S. Isidoro, Trescore Balneario, Bergamo, Italy

^c Department of Neuroscience Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy

^d Division of Pharmacology, Department of molecular and Translational Medicine, University of Brescia, Brescia, Italy

^e Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway and Department of Old Age Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK

^f Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology,
The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

^g Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

^h Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK

ⁱ UK Dementia Research Institute at UCL, London, UK

^j Wallenberg Centre for Molecular and Translational Medicine, Department of Psychiatry and
Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the
University of Gothenburg, Sweden

^k King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl
Clinical Neuroscience Institute, London, UK

^l NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for
Dementia at South London & Maudsley NHS Foundation, London, UK

***Corresponding author:**

Andrea Pilotto, MD

Neurology Unit

Department of Clinical and Experimental Sciences

University of Brescia

P.zale Spedali Civili, 1 - 25123 Brescia, Italy

Ph. +39-030-3995632

Fax +39-030-3995027

Email: pilottoandreae@gmail.com

[§]Andrea Pilotto and Alberto Imarisio equally contributed to the present work.

Running Title: Plasma NfL predicts cognitive progression in DLB

Word Count Manuscript: 1976 words **Abstract:** 105 words

Number of references: **Figures:** 1 **Tables:** 2 + 1 supplementary table.

Keywords: Dementia with Lewy Bodies; neurofilament light chain; cognitive progression; biomarkers.

Authorship

Andrea Pilotto: study concept and design, acquisition of data, analysis and interpretation of data, drafting/revising the manuscript for content.

Alberto Imarisio: study concept and design, acquisition of data, analysis and interpretation of data, drafting/revising the manuscript for content.

Claudia Carrarini: acquisition of data, drafting/revising the manuscript for content.

Mirella Russo: acquisition of data, drafting/revising the manuscript for content.

Stefano Masciocchi: acquisition of data, drafting/revising the manuscript for content.

Stefano Gipponi: acquisition of data, drafting/revising the manuscript for content.

Elisabetta Cottini: acquisition of data, drafting/revising the manuscript for content.

Dag Aarsland: drafting/revising the manuscript for content.

Henrik Zetterberg: study concept and design, acquisition of data, analysis and interpretation of data, drafting/revising the manuscript for content.

Nicholas Ashton: acquisition of data, analysis and interpretation of data, drafting/revising the manuscript for content.

Abdul Hye: acquisition of data, analysis and interpretation of data, drafting/revising the manuscript for content.

Laura Bonanni: acquisition of data, analysis and interpretation of data, drafting/revising the manuscript for content.

Alessandro Padovani: acquisition of data, analysis and interpretation of data, drafting/revising the manuscript for content.

ABSTRACT

Plasma neurofilament light chain (NfL) is a marker of neuronal damage in different neurological disorders and might predict disease progression in dementia with Lewy bodies (DLB). The study enrolled 45 controls and 44 DLB patients (including 17 prodromal cases) who underwent an extensive assessment at baseline and at 2 years follow-up. At baseline, plasma NfL levels were higher in both probable DLB and prodromal cases compared to controls. Plasma NfL emerged as the best predictor of cognitive decline compared to age, sex and baseline severity variables. The study supports the role of plasma NfL as a useful prognostic biomarker from the early stages of DLB.

INTRODUCTION

Dementia with Lewy Bodies (DLB) is a complex neurodegenerative disorder characterized pathologically by misfolding and aggregation of alpha-synuclein, as well as A-beta and tau proteins, and by a combination of cognitive deficits with fluctuations, visual hallucinations, parkinsonism, REM-sleep behavior disorder (RBD) which represent the core clinical symptoms and is often associated with behavioral abnormalities and autonomic symptoms [1–4]. The prognosis is poor [5] and the variation in cognitive decline is large [6].

Despite the recent advances in the clinical definition of DLB from prodromal stages, disentangling the heterogeneity of presentation and disease progression of patients is still a great challenge for the research community [3].

Diagnosing and stratifying DLB patients are pivotal for a proper personalization of management strategies and identifying patients with different rate of progression will enable a proper selection of patients in incoming disease-modifying interventions.

Neurofilament light chain (NfL), a highly expressed protein in large caliber myelinated axons, has been recently proposed as general marker of neuronal degeneration and damage in different neurological disorders [7,8]. In fact, CSF and plasma NfL levels are significantly altered in Alzheimer's disease (AD), prion diseases, amyotrophic lateral sclerosis, frontotemporal dementia, whereas findings in Parkinson's disease (PD) and early DLB were contradictory [9]. In addition to that, it has been reported that plasma and CSF NfL levels correlated with disease severity and progression in PD [8,10,11] and Alzheimer's disease [12]. Very few studies have focused on DLB patients and, to the best of our knowledge, no prospective longitudinal studies evaluated plasma NfL as potential early diagnostic and prognostic marker in DLB. Therefore, the aim of the present study was to investigate the relationships between plasma NfL and motor and cognitive symptoms in DLB from the prodromal stage and to evaluate its accuracy as predictor of progression after two-years of follow-up.

METHODS

Patients selection and assessment

Consecutive patients with a clinical diagnosis of probable DLB [2] or prodromal DLB [3] were enrolled between October 2016 and March 2018 for the baseline evaluation at the Neurology Unit at the University of Brescia, Italy and the Neurology Unit at the University G. d'Annunzio of Chieti-Pescara, Chieti, Italy. Healthy controls subjects (HC) with normal cognitive and motor functions were recruited among patients' caregivers. This study was approved by the local ethics committee (NP 1471, DMA, Brescia) and was in conformity with the Helsinki Declaration; informed consent was obtained from all participants. All patients underwent routine blood analyses, magnetic resonance imaging (MRI) and [¹²³I]FP-CIT SPECT imaging supporting the diagnosis [13]; levodopa equivalent daily dose (LEDD) was calculated according to standard conversion [14] and the diagnosis was supported by at least one year of clinical follow-up.

The following exclusion criteria were applied: (1) cognitive deficits or dementia due to other causes than DLB; (2) prominent cortical or subcortical infarcts or brain/iron accumulation at imaging; (3) other neurologic disorders or medical conditions potentially associated with cognitive deficits; (4) bipolar disorder, schizophrenia, history of drug or alcohol abuse or impulse control disorder; (5) recent traumatic events or acute fever/inflammation (potentially influencing NfL levels).

At baseline, standardized neurological examination was performed, including the Movement Disorder Society- Unified Parkinson Disease Rating Scale, part III (MDS-UPDRS, part III) [15], a full neuropsychological assessment including the Mini-Mental State Examination (MMSE), the Neuropsychiatric Inventory (NPI) for the assessment of global cognitive and psychiatric functions [16] and an evaluation of basic and instrumental activities of daily living [17]. DLB patients without dementia (i.e., independent in activities of daily living) at baseline

and two years - follow-up were retrospectively re-classified as prodromal DLB according to recently proposed diagnostic criteria [3].

All patients included in the analyses underwent a clinical follow-up at 2 years including full neurological examination, motor, cognitive and behavioural assessment.

Biochemical analyses

At the time of assessment, approximately 10 mL venous blood was collected in glass tubes containing sodium ethylenediaminetetraacetic acid (EDTA) from each subject. The blood samples were centrifuged at 2000 x g at 4 °C for 8 min within 2 h of collection. Plasma supernatant was collected, divided into aliquots, and frozen at – 80 °C until further use. Plasma NfL concentration was measured using the Simoa HD-1 platform (NF-Light; Quanterix, Billerica, MA) at the Maurice Wohl Clinical Neuroscience Institute, London, UK. Samples were randomized, blinded and measured in duplicate using a batch of reagents from the same lot. The intra-assay and inter-assay coefficients of variation were 8.1 and 11.2%, respectively. The lower limit of quantification was 0.136 pg/mL and the lower limit of quantification (LLOQ) was 0.696 pg/mL when compensated for a 4-fold sample dilution. Outliers with plasma NfL value above more than 5 standard deviations of the mean were excluded from the study analysis (n = 1 probable DLB; n = 1 HC) [18].

Statistical analyses.

Group differences between HC and total DLB, as well as between probable DLB and prodromal DLB were assessed with Mann-Whitney U test or Fisher exact test for continuous or dichotomous variables, respectively. Plasma NfL levels between groups were compared with age-adjusted one-way ANOVA. Progression of MMSE, MDS-UPDRS-III and NPI between groups was evaluated with repeated measures ANOVA adjusted for age, sex, disease duration, baseline MMSE and MDS-UPDRS-III (for MMSE and MDS-UPDRS-III

progression) and for age, sex, disease duration, baseline MMSE and baseline NPI (for NPI progression).

Plasma NfL levels and established prognostic factors (age, gender, disease duration, MDS-UPDRS III score, MMSE and NPI) were analyzed by a multivariable linear regression in order to evaluate the best predictors of changes within cognitive (MMSE), behavioral (NPI) and motor (MDS-UPDRS-III) scores at two years. Significance was set at $p < 0.05$ for all the analysis. SPSS 24 (IBM, Armonk, NY) was used for statistical analyses.

RESULTS

Recruitment, clinical and cognitive baseline features

Forty-four DLB patients (including 27 with dementia and 17 prodromal cases) and forty-five healthy controls were consecutively enrolled. Three patients deceased during the follow-up and 41 patients were thus included in the longitudinal analyses. Between prodromal DLB patients ($n = 17$), $n = 13$ were diagnosed as probable MCI-LB, $n = 3$ as psychiatric-onset prodromal DLB and $n = 1$ as delirium-onset prodromal DLB. Clinical and demographic features of DLB with dementia and prodromal cases are shown in Table 1. According to the definition, prodromal cases were independent for activities of daily living and exhibited higher total MMSE scores compared to DLB with dementia (25.5 ± 1.3 vs 18.3 ± 3.7 ; $p = 0.001$). HC were slightly younger than DLB patients (73.3 ± 7.6 vs 77.5 ± 5.4 years respectively, $p = 0.003$) and comparable for sex distribution (44.4% vs 40.9% males respectively, $p = 0.736$). In age-adjusted comparisons, NfL levels were higher in DLB total cohort and separately in both probable DLB and prodromal cases compared to HC (Figure 1 and Table 1, HC 25.7 ± 10.5 pg/ml, DLB with dementia 55.3 ± 20.9 pg/ml, prodromal DLB

46.9 ± 23.2 pg/ml; total DLB vs HC: $p < 0.001$; prod-DLB vs HC: $p = 0.001$; probable DLB vs HC: $p < 0.001$).

In total DLB cohort, plasma NfL correlated with age ($r = 0.369$; $p = 0.014$) and exhibited similar distribution in male and female subjects. At the time of baseline assessment, no correlation between NfL levels and disease duration or severity of motor, cognitive and neuropsychiatric features was detected in analyses adjusted for age and sex (in the whole group and separately for prodromal and clinical cases).

Plasma NfL as predictor of progression

At follow up, the total group of DLB patients exhibited a mean decrease of 3.8 ± 3.1 points at MMSE score, a mean increase of 1.6 ± 1.5 points in total NPI and 2.8 ± 6.8 points in MDS-UPDRS-III score. In the model without NfL (model 1, supplementary Table 1), no predictors of changes in MMSE were identified ($R^2 = 0.160$) while the inclusion of NfL (model 2) increased the prediction of the linear model ($R^2 = 0.356$) and age ($p = 0.047$) and NfL ($p = 0.034$) were the only significant predictors of changes in MMSE (Table 2). No predictors of NPI progression were detected in linear regression model, whereas male gender was the only predictor of Δ MDS-UPDRS-III in the model with ($\beta = 0.387$, $p = 0.023$) and without ($\beta = 0.373$, $p = 0.026$) the inclusion of NfL.

At follow-up, 10 out of 17 prodromal cases converted to dementia with Lewy bodies; converters did not differ for demographic or clinical baseline variables and exhibited slightly higher but not significant NfL levels compared with non-converters (51.4 ± 22.9 vs 40.5 ± 23.9 ; $p = 0.37$).

DISCUSSION

This is the first longitudinal study addressing plasma NfL as an early diagnostic and prognostic marker in DLB patients. We found higher NfL levels in DLB patients compared with controls from the prodromal stages and we demonstrated for the first time that baseline NfL levels predicted cognitive decline over a follow-up of 2 years.

The study included consecutive patients with a clinical diagnosis of probable DLB and a subset of prodromal cases who underwent an extensive motor, cognitive and behavioral assessment. We demonstrated that clinical DLB cases exhibited increased plasma NfL levels compared with controls, in line with several cross-sectional studies focused on neurodegenerative disorders [7,19]. Furthermore, the findings showed that cases who retrospectively fulfilled the newly proposed prodromal DLB criteria [3] exhibited already increased plasma NfL levels compared with controls. These important results strongly support the usefulness of plasma NfL as diagnostic marker of DLB already in the prodromal stages, in line with the work of Delaby and colleagues [21] based on CSF data on DLB with and without dementia.

In addition, our study aimed to define whether plasma NfL levels might be of prognostic value, a still unsolved issue with great relevance for the upcoming disease-modifying trials. Indeed, the identification of consistent disease progression markers is still an open challenge for DLB. Recently, a growing number of studies identified EEG, imaging or CSF abnormalities to be associated with faster progression already in early DLB stages [22–24]. However, these techniques definitively need further validations to be applied in clinical practice.

In the present study, we identified higher blood NfL levels as a significant predictor of faster cognitive progression in DLB patients at 2 year follow-up. These results were strengthened by a linear regression model taking into account age, sex and the baseline clinical data for both clinical and prodromal DLB patients. These findings are at variance with two earlier studies

performed on CSF, that failed to demonstrate a relationship between NfL levels and annual MMSE decline [25][26] in smaller group of DLB patients. Of note, the prognostic value of NfL was specifically demonstrated for cognitive changes, whereas was not confirmed for behavioral and motor progression in the cohort. This fit with data coming from studies on Alzheimer's disease [12] but also with Parkinson's disease in which higher NfL levels have been more consistently associated with cognitive decline [10].

Several limitations should be acknowledged. First, a 2-year follow-up period is a short interval to consider these findings as definitive, and further validations in longer and larger longitudinal multicentre studies are needed in order to evaluate the long-term value of NfL in predicting progression on disability milestones. Second, the small sample size required the use of non-parametric statistical analysis and limited the number of covariates in linear regression model, and since this was an exploratory study we did not adjust for multiple statistical comparisons. Third, the study evaluated clinical outcomes and the findings need to be replicated against imaging, CSF or neurophysiological or other promising peripheral markers, such as P-Tau [12,27]. Diagnosis was clinical associated with DAT imaging but without autopsy confirmation, and the prodromal criteria were applied retrospectively. However, the longitudinal design and standardized comprehensive clinical assessments and use of the most recent consensus diagnostic criteria ensures a high diagnostic accuracy. Limitations notwithstanding, this is the first study demonstrating the diagnostic and prognostic value of plasma NfL in DLB already from prodromal stages.

ACKNOWLEDGMENTS

The authors thanks all the participants for their participation.

Study funding: The recruitment of patients was partially supported by BIOMANE Project from the Health and Wealth research grants 2016 of the University of Brescia [grant number NP 1471, DMA].

Relevant conflicts of interest/financial disclosures (for the past two years): all the authors report no disclosures related to this manuscript. Other disclosures are reported below.

Andrea Pilotto served in the advisory board of Z-cube (technology division of Zambon pharmaceuticals); he received honoraria from Z-cube s.r.l., Biomarin, Zambon, Nutricia and Chiesi pharmaceuticals. He received research support from Vitaflo Germany and Zambon Italy.

Alberto Imarisio has no financial conflicts to disclose.

Claudia Carrarini has no financial conflicts to disclose.

Mirella Russo has no financial conflicts to disclose.

Stefano Masciocchi has no financial conflicts to disclose.

Stefano Gipponi has no financial conflicts to disclose.

Elisabetta Cottini has no financial conflicts to disclose.

Dag Aarsland has received research support and/or honoraria from Astra-Zeneca, H.

Lundbeck, Novartis Pharmaceuticals, Evonik, and GE Health, and served as paid consultant for H. Lundbeck, Eisai, Heptares, Mentis Cura, Eli Lilly and Biogen.

Henrik Zetterberg has served at scientific advisory boards for Denali, Roche Diagnostics,

Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).

Nicholas Ashton has no financial conflicts to disclose.

Abdul Hye has no financial conflicts to disclose.

Laura Bonanni received unrelated national grants from the Italian Ministry of Health, from European Commission (PD MIND project, IMI call) and from Mentis cura, Oslo srl; fees from G.E. Healthcare for teaching courses. Served as reviewer for NIH has no financial conflicts to disclose.

Alessandro Padovani is consultant and served on the scientific advisory board of GE Healthcare, Eli-Lilly and Actelion Ltd Pharmaceuticals, received speaker honoraria from Nutricia, PIAM, Lansgstone Technology, GE Healthcare, Lilly, UCB Pharma and Chiesi Pharmaceuticals. He is founded by Grant of Ministry of University (MURST).

REFERENCES

- [1] Walker Z, Possin KL, Boeve BF, Aarsland D (2015) Lewy body dementias. *Lancet* **386**, 1683–1697.
- [2] McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K (2017) Diagnosis and management of dementia with Lewy bodies. *Neurology* 10.1212/WNL.0000000000004058.

- [3] McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, Kantarci K, Muscio C, O'Brien JT, Postuma RB, Aarsland D, Ballard C, Bonanni L, Donaghy P, Emre M, Galvin JE, Galasko D, Goldman JG, Gomperts SN, Honig LS, Ikeda M, Leverenz JB, Lewis SJG, Marder KS, Masellis M, Salmon DP, Taylor JP, Tsuang DW, Walker Z, Tiraboschi P (2020) Research criteria for the diagnosis of prodromal dementia with Lewy bodies. *Neurology* **94**, 743–755.
- [4] Pilotto A, Romagnolo A, Tuazon JA, Vizcarra JA, Marsili L, Zibetti M, Rosso M, Rodriguez-Porcel F, Borroni B, Rizzetti MC, Rossi C, Vizcarra-Escobar D, Molano JR, Lopiano L, Ceravolo R, Masellis M, Espay AJ, Padovani A, Merola A (2019) Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in α -synucleinopathies. *J Neurol Neurosurg Psychiatry* **90**, 1257-1263.
- [5] Mueller C, Ballard C, Corbett A, Aarsland D (2017) The prognosis of dementia with Lewy bodies. *Lancet Neurol* **16**, 390–398.
- [6] Giil LM, Aarsland D (2020) Greater Variability in Cognitive Decline in Lewy Body Dementia Compared to Alzheimer's Disease. *J Alzheimer's Dis* **73**, 1321–1330.
- [7] Ashton N, Janelidze S, Al Khleifat A, Leuzy A, Van Der Ende E, Karikari T, Benedet A, Pascoal T, Lleó A, Galimberti D, Bonanni L, Pilotto A, Padovani A, Lycke J, Novakova L, Axelsson M, Velayudhan L, Rabinovici G, Miller B, Pariante C, Resnick S, Schöll M, Fernandez-Eulate G (2021) Diagnostic value of plasma neurofilament light: A multicentre validation study. *Unpubl data*.
- [8] Mollenhauer B, Dakna M, Kruse N, Galasko D, Foroud T, Zetterberg H, Schade S, Gera RG, Wang W, Gao F, Frasier M, Chahine LM, Coffey CS, Singleton AB, Simuni T, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kiebertz K, Marek K, Siderowf A, Cedarbaum JM, Hutten SJ, Trenkwalder C, Graham D (2020) Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. *Mov Disord* **35**, 1999–2008.

- [9] Bridel C, Van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, Van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ (2019) Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. *JAMA Neurol* **76**, 1035–1048.
- [10] Lin CH, Li CH, Yang KC, Lin FJ, Wu CC, Chieh JJ, Chiu MJ (2019) Blood NfL: A biomarker for disease severity and progression in Parkinson disease. *Neurology* **93**, e1104–e1111.
- [11] Bäckström D, Linder J, Jakobson Mo S, Riklund K, Zetterberg H, Blennow K, Forsgren L, Lenfeldt N (2020) NfL as a biomarker for neurodegeneration and survival in Parkinson disease. *Neurology* **95**, e827–e838.
- [12] Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero Rodríguez J, Snellman A, Suárez-Calvet M, Blennow K, Zetterberg H, Schöll M (2021) Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain with Neurodegeneration in Alzheimer Disease. *JAMA Neurol*.
- [13] Pilotto A, Cola FS di, Premi E, Grasso R, Turrone R, Gipponi S, Scalvini A, Cottini E, Paghera B, Garibotto V, Rizzetti MC, Bonanni L, Borroni B, Morbelli S, Nobili F,

- Guerra UP, Perani D, Padovani A (2019) Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. *Eur J Nucl Med Mol Imaging*.
- [14] Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. *Mov Disord* **25**, 2649–53.
- [15] Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N, Movement Disorder Society UPDRS Revision Task Force (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord* **23**, 2129–70.
- [16] Cummings JL (1997) The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. *Neurology* **48**,.
- [17] Pilotto A, Turrone R, Liepelt-Scarfone I, Bianchi M, Poli L, Borroni B, Alberici A, Premi E, Formenti A, Bigni B, Cosseddu M, Cottini E, Berg D, Padovani A (2016) Vascular risk factors and cognition in Parkinson's disease. *J Alzheimer's Dis* **51**,.
- [18] Hodge VJ, Hodge VJ, Austin J (2004) A survey of outlier detection methodologies. *Artif Intell Rev* **22**, 2004.
- [19] Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, Staufenbiel M, Neumann M, Maetzler W, Kuhle J, Jucker M (2016) Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. *Neuron* **91**, 56–66.
- [20] Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C,

- Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J (2017) Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. *Ann Neurol* **81**, 857–870.
- [21] Delaby C, Alcolea D, Carmona-Iragui M, Illán-Gala I, Morenas-Rodríguez E, Barroeta I, Altuna M, Estellés T, Santos-Santos M, Turon-Sans J, Muñoz L, Ribosa-Nogué R, Sala-Matavera I, Sánchez-Saudinos B, Subirana A, Videla L, Benejam B, Sirisi S, Lehmann S, Belbin O, Clarimon J, Blesa R, Pagonabarraga J, Rojas-Garcia R, Fortea J, Lleó A (2020) Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. *Sci Rep* **10**, 1–8.
- [22] Bonanni L, Perfetti B, Bifulchetti S, Taylor J, Franciotti R, Parnetti L, Thomas A, Onofri M (2015) Neurobiology of Aging Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies. *Neurobiol Aging* **36**, 434–445.
- [23] van der Zande JJ, Gouw AA, van Steenoven I, van de Beek M, Scheltens P, Stam CJ, Lemstra AW (2020) Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies. *Neurology* **95**, e662–e670.
- [24] Nedelska Z, Schwarz CG, Lesnick TG, Boeve BF, Przybelski SA, Lowe VJ, Kremers WK, Gunter JL, Senjem ML, Graff-Radford J, Ferman TJ, Fields JA, Knopman DS, Petersen RC, Jack CR, Kantarci K (2019) Association of Longitudinal β -Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. *JAMA Netw open* **2**, e1916439.
- [25] Olsson B, Portelius E, Cullen NC, Sandelius Å, Zetterberg H, Andreasson U, Höglund K, Irwin DJ, Grossman M, Weintraub D, Chen-Plotkin A, Wolk D, McCluskey L, Elman L, Shaw LM, Toledo JB, McBride J, Hernandez-Con P, Lee VMY, Trojanowski JQ, Blennow K (2019) Association of Cerebrospinal Fluid Neurofilament Light Protein

Levels with Cognition in Patients with Dementia, Motor Neuron Disease, and Movement Disorders. *JAMA Neurol* **76**, 318–325.

- [26] Abu-Rumeileh S, Capellari S, Stanzani-Maserati M, Polischi B, Martinelli P, Caroppo P, Ladogana A, Parchi P (2018) The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. *Alzheimer's Res Ther* **10**,.
- [27] Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J, Schöll M, Massarweh G, Soucy JP, Höglund K, Brinkmalm G, Mattsson N, Palmqvist S, Gauthier S, Stomrud E, Zetterberg H, Hansson O, Rosa-Neto P, Blennow K (2020) Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *Lancet Neurol* **19**, 422–433.

Table 1. Clinical and demographic characteristics of prodromal DLB and probable DLB patients at baseline and after 2-years follow-up.

	Total (n = 44)	Prodromal DLB (n = 17)	Probable DLB (n = 27)	p - value
Age, years	77.5 ± 5.4	77.2 ± 4.8	77.7 ± 5.8	0.181 ^a
Sex M, n (%)	18 (40.9)	9 (52.9)	9 (33.3)	0.225 ^b
Disease duration, years	3.8 ± 3.0	3.4 ± 3.0	4.1 ± 3.0	0.256 ^a
NfL, pg/ml	52.0 ± 22.0	46.9 ± 23.2	55.3 ± 20.9	0.181 ^a
Independence in functional activities, n (%)	15 (34.1)	17 (100)	0 (0)	< 0.001 ^b
MMSE, total score	21.2 ± 4.6	25.5 ± 1.3	18.3 ± 3.7	< 0.001 ^a
NPI total score	20.5 ± 16.1	15.2 ± 10.1	23.6 ± 18.3	0.191 ^a
MDS-UPDRS-III, total score	24.8 ± 13.6	23.1 ± 11.6	26.0 ± 14.8	0.655 ^a
LEDD, mg/day	254.2 ±	240.0 ± 213.1	262.7 ± 222.9	0.818 ^a
Follow-up at two years				
ΔMMSE	-3.8 ± 3.1	-3.9 ± 3.1	- 3.8 ± 3.1	0.856 ^c
ΔNPI	1.6 ± 1.5	1.2 ± 1.6	4.8 ± 3.5	0.151 ^c
ΔMDS-UPDRS-III	2.8 ± 6.8	2.4 ± 7.2	3.2 ± 6.8	0.755 ^c

Abbreviations: MDS-UPDRS-III, Movement Disorder Society Unified Parkinson’s Disease

Rating Scale, part III; ΔMDS-UPDRS-III = (MDS-UPDRS-III_{2 years} - MDS-UPDRS-III_{baseline});

MMSE, Minimental State Examination; Δ MMSE = (MMSE_{2years} – MMSE_{baseline}); NfL, neurofilament light chain; NPI = neuropsychiatric inventory; Δ NPI = (NPI_{2years} – NPI_{baseline}).


[§] Comparison between prodromal and probable DLB subgroups have been performed by ^a Mann-Whitney *U* test or ^b Fisher exact test or ^c repeated measures model adjusted for the effect of age, sex, disease duration, baseline MDS-UPDRS-III, baseline MMSE (for Δ MDS-UPDRS-III and Δ MMSE) and for age, sex, disease duration, baseline MDS-UPDRS-III, baseline MMSE and baseline NPI (for Δ NPI).

Table 2. Multivariable linear regression model for cognitive progression in total DLB cohort defined by changes in MMSE score including demographic, clinical baseline variables and plasma NfL levels.

Independent variables	B	Standard error	Beta	t	p-value
Constant	-18,484	8,163		-2,264	0,030
age	0,204	0,099	0,348	2,065	0,047
Gender	1,444	0,947	0,236	1,524	0,137
Disease duration	-0,284	0,171	-0,294	-1,657	0,107
MMSE_{baseline}	-0,026	0,109	-0,038	-0,239	0,813
MDS-UPDRS-III_{baseline}	0,043	0,037	0,193	1,152	0,258
NfL	-0,050	0,022	-0,361	-2,218	0,034

Abbreviations: MDS-UPDRS-III, Movement Disorder Society Unified Parkinson’s Disease Rating Scale, part III; MMSE, Minimental State Examination. NfL, neurofilament light chain.

Figure 1. Box and whiskers plot showing plasma NfL levels in HC, prod-DLB and DLB patients.



Data are shown as medians with 25°–75° percentiles (boxes), min-max values (whiskers) and individual values (dots). DLB = probable Dementia with Lewy Bodies; HC = healthy controls; NfL = neurofilament light chain; prod-DLB = prodromal Dementia with Lewy Bodies; * $p = 0.001$; ** $p < 0.001$.

Supplementary Table 1

Multivariable linear regression for factors associated with cognitive, motor and behavioral progression.

Model a) included demographic and clinical variables but no NfL at baseline for cognitive progression in total DLB cohort defined by changes within MMSE score. Models b) and c)

showed the predicting models of motor progression defined by MDS-UPDRS-III (b) and behavioral abnormalities defined by NPI changes (c)

a) Model for MMSE changes without NfL

Independent variables	B	Standard error	Beta	t	p-value
Constant	-16,094	8,558		-1,881	0,069
age	0,143	0,100	0,244	1,428	0,163
Gender	1,191	0,994	0,195	1,198	0,239
Disease duration	-0,290	0,181	-0,300	-1,602	0,119
MMSE_{baseline}	-0,010	0,115	-0,015	-0,087	0,931
MDS-UPDRS-III_{baseline}	0,035	0,039	0,159	0,902	0,374

b) Model for MDS-UPDRS-III changes with NfL

Constant	35,693	19,178		1,861	0,072
Age	-0,301	0,232	-0,229	-1,297	0,204
Gender	-5,302	2,225	-0,387	-2,383	0,023
Disease duration	-0,077	0,403	-0,036	-0,192	0,849
MMSE_{baseline}	-0,151	0,256	-0,099	-0,589	0,560
MDS-UPDRS-III_{baseline}	0,007	0,088	0,014	0,083	0,935
NfL	0,039	0,053	0,126	0,736	0,467

c) Model for NPI changes with NfL

Constant	-4,968	36,745		-0,135	0,893
age	0,370	0,440	0,162	0,841	0,408
Gender	-5,784	4,065	-0,239	-1,423	0,166
Disease duration	-0,507	0,774	-0,134	-0,655	0,518
MMSE_{baseline}	0,157	0,488	0,059	0,322	0,750

MDS-UPDRS-III _{baseline}	-0,119	0,155	-0,139	-0,766	0,450
NPI total score _{baseline}	-0,158	0,146	-0,210	-1,081	0,289
NfL	-0,138	0,094	-0,263	-1,472	0,153

Abbreviations: MDS-UPDRS-III, Movement Disorder Society Unified Parkinson’s Disease Rating Scale, part III; MMSE, Minimental State Examination; NfL, neurofilament light chain; NPI, neuropsychiatric inventory.